Dr. Reddys Laboratories is currently trading at Rs. 2943.20, up by 73.05 points or 2.55% from its previous closing of Rs. 2870.15 on the BSE.
The scrip opened at Rs. 2925.00 and has touched a high and low of Rs. 2945.00 and Rs. 2874.30 respectively. So far 16003 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2990.00 on 27-Nov-2019 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.
Last one week high and low of the scrip stood at Rs. 2969.00 and Rs. 2850.00 respectively. The current market cap of the company is Rs. 48776.66 crore.
The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.04% and 14.03% respectively.
Dr. Reddy's Laboratories has launched Bortezomib for Injection 3.5 mg/vial, approved by the US Food and Drug Administration (USFDA) via a 505(b) (2) new drug application (NOA) pathway for intravenous use only.
The company’s Bortezomib for Injection 3.5 mg/vial is for intravenous use only and is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharm aceuticals in India and overseas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1504.25 |
Dr. Reddys Lab | 6263.70 |
Cipla | 1406.25 |
Zydus Lifesciences | 948.20 |
Lupin | 1615.85 |
View more.. |